Myelosuppression is the dose-limiting toxicity for nitrosourea chemotherapy. This toxicity predominantly involves modification of the 0' position of guanine with an alkyl moiety. The enzyme responsible for repair of 0'-alkylguanine adducts, O'-alkylguanine-DNA alkyltransferase (alkyltransferase), is expressed at low levels in bone marrow (BM) cells. High alkyltransferase expression prevents the cytotoxicity and carcinogenicity of nitrosoureas in several transgenic and in vitro gene transfer models. We used gene transfer using a novel myeloproliferative sarcoma virus (MPSV) based retrovirus (vM5MGMT) to express the human alkyltransferase cDNA (MGMT) in human and murine hematopoietic cells.
HE OBSERVATION that myelosuppression is the doselimiting toxicity for many chemotherapeutic agents has led to consideration of transferring drug resistance genes into hematopoietic precursors. For instance, the multiple drug resistance gene 1 (MDRI) codes for the p-glycoprotein transmembrane pump responsible for transporting lipophilic compounds, including many naturally occurring chemotherapeutic agents, out of the cell.' Transgenic mice that express the human MDRI cDNA at high levels within bone marrow (BM) cells are resistant to the toxicity induced by several of these agent^.^,',^ Expression has also been increased by transduction of MDRl into murine hematopoietic progenitors using retroviral vectors.5-* Transduced BM cells show increased resistance to agents such as taxol both in vitro and, after BM transplantation, in vivo.'-* In addition, it has recently been shown by Ward et al' that CD34+ progenitors transduced with a retrovirus containing the human MDRI cDNA can be enriched for cells expressing high MDRI levels in vitro by treatment with taxol.
Overexpression of MDRI does not increase resistance to alkylating agents. Rather, resistance is mediated by DNA repair enzymes, glutathione and glutathione-S-transferases, and polyamines. DNA repair is particularly important for one class of alkylating agents-the nitrosoureas, triazines, and tetrazines. These agents form a variety of DNA adducts, but the predominant mutagenic and cytotoxic lesion is in-transduced K562 cells. Primary murine BM progenitors showed a high transduction efficiency with vM5MGMT and have increased BCNU resistance in vitro. After BM transplantation with vM5MGMT-transduced BM cells and BCNU treatment of these mice, BM, spleen and thymus had a 10-to 40-fold increase in alkyltransferase expression that persisted for at least 23 weeks posttransplantion. Progenitor cells procured from mice expressing high levels of alkyltransferase also had increased resistance to BCNU. Thus, an MPSVbased retroviral vector transduces mouse and human hematopoietic cells at high efficiency and results in high levels of gene expression both in vitro and in vivo. Overexpression of the alkyltransferase protein may protect hematopoietic progenitors from nitrosourea-induced myelosuppression. duced by attack at the 0' position of guanine (G).'" Decomposition of methylating agents such as procarbazine or streptozotocin, liberates a methyl (m) diazonium ion, forming 06mG," whereas with chloroethylating agents such as 1,3bis (2-chloroethyl) nitrosourea (BCNU), a chloroethyl group is liberated, forming O'chloroethylG.'* In the absence of DNA repair, 06mG preferentially base pairs with thymine (T) during DNA replication, ultimately leading to a G-to-A point mutation,I3 or the 06mG:T is recognized by the mismatch repair system and abortively replaced with a cytosine (C) without repair of the O'mG adduct resulting in cytotoxicity. On the other hand, the 06-chloroethylG adduct undergoes rearrangement to N'O'ethanoguanine, which is then converted to a very cytotoxic interstrand crosslink."
The DNA repair protein 06alkylguanine-DNA alkyltransferase (alkyltransferase) (E.C. 2.1.1.63)
is the main repair enzyme involved in removing these DNA le~ions.'~~'' The alkyltransferase covalently transfers the 06alkylguanine adduct to a cysteine residue within its active site, leaving a normal guanine residue in the DNA. This results in irreversible inactivation of the protein and hence a one-to-one relationship between the number of adducts repaired and the number of alkyltransferase molecules in the nucleus. I6 We have shown that the chemosensitivity of BM cells to the nitrosoureas is caused by low levels of alkyltransferase in hematopoietic precursor^.'^^" As a precedent for the studies described here, we have expressed both the bacterial and human alkyltransferase proteins in mammalian cells and in transgenic mice. Overexpression of the alkyltransferase protein protected cells from nitrosourea induced cytotoxicity. For instance, when bacterial alkyltransferase, coded by the ada gene, was expressed at high levels in NIH 3T3, CCL-I and rat kidney NRK cell lines after retroviral transduction, these cells became more resistant to BCNU cytotoxicity.*'),*' Expression of ada in the liver of transgenic mice lowered the levels of persistent 0'methylguanine adducts in transgenic mice treated with methylnitrosourea.22 Overexpression of the human alkyltransferase gene resulted in a 100-fold protection against BCNU cytotoxicity and a 25% decrease in mutation frequency as compared with untransfected Chinese hamster ovary (CHO) cells.23 Finally, in a model of secondary leukemias in humans, transgenic mice that overexpress MGMT in the thymus were markedly protected from developing methlynitrosourea-induced thymic High-efficiency retroviral gene transduction of hematopoietic progenitor cells has been achieved for several species, including mice, monkeys, and Most vectors use the Moloney murine leukemia virus (MoMuLV) back-b~n e ,~' .~' and in many cases gene expression in primary BM cells, both in vitro and in vivo, is quite For this reason, we used the myeloproliferative sarcoma virus backbone (MPSV), a retrovirus with a wider host expression range than MoMuLV vectors, caused, at least in part, by point mutations in the transcriptional control U3 region of the long terminal repeat (LTR).35 MPSV has been used to express granulocyte-macrophage colony-stimulating factor (GM-CSF) in factor-dependent myeloid cell lines36 and by Clapp et a137 to evaluate the ontogeny of hematopoietic stem cells in mouse BM and in rat fetal liver. In this study we show that the MGMT gene expressed from MPSV expresses alkyltransferase at high levels and results in decreased BCNU cytotoxicity in K562 cells and primary murine hematopoietic progenitor cells both in vitro and in vivo. Fig 1, pM5MGMT was constructed from pM5ne0, derived from MPSV (kindly provided by Dr C. S t o~k i n g~~) . The backbone contains the neomycin resistance gene (neo) driven off the MPSV 5' LTR, two unique cloning sites (BamHI and EcoRI) upstream of the neo gene, a packaging site that extends into the gag gene ($') and splice donor and acceptor sites. Two transcripts are driven off the MPSV LTR; one encodes the full-length provirus, whereas the spliced transcript encodes neo only. The human alkyltransferase cDNA (MGMT) was cloned from the alkyltransferase expressing colon cancer cell line, Vac0 6 (kindly provided by Dr J.K.V. Willson) using RNA-polymerase chain reaction (PCR),23 and inserted into the BamHI site of pM5neo in the same orientation as the 5' LTR. Virus producing cell lines were made by transfecting pM5MGMT DNA into the ecotropic-producing GP + E8638 and amphotropic-producing GP + e n~A M 1 2~~ lines. To increase viral titer, a modified supernatant "ping-pong" method was used.@ Clones were selected in G418, titered by limiting dilution on NIH 3T3 cells for G418 resistance, and assayed for MGMT expression by Northern blot and for alkyltransferase activity. pM5lac was constructed as previously described3' and contains the bacterial lacZ gene in place of the MGMT cDNA. Both GP + E86 and GP + envAM12 cell lines producing vM5lac were isolated as described above.
MATERIALS AND METHODS

Virus. As shown in
Helper virus assays. Supernatant from virally-infected NIH 3T3, K562, and mouse BM cells (BM), and serum from mice transplanted with virally-infected BM cells were used to infect NIH 3T3 cells to detect infectious virus. NIH-lac cells, an NIH 3T3 cell line containing a lacZ provirus, were also infected with the above supernatant and serum to detect proviral rescue. Secondary supernateinfected NIH 3T3 cells were ( l ) selected in 1 mg/mL G418 and scored for colony growth, (2) procured for DNA to detect proviral sequences by PCR amplification, or (3) cultured for 1 month at which time supernatant was reassayed for viral particles. Supernatant from secondary supernate NIH-lac-infected cells was used to infect NIH 3T3 cells that were stained with X-gal to detect lacZ+ pgalactosidase-expressing cells. Supernatant from both ecotropic and amphotropic vM5MGMT producers was assayed in this manner bimonthly from virus collections used for experimentation. At no time was replication-competent retrovirus derived from vM5MGMT detected using the above assays, with a limit of detection of approximately 2 X 1O"j colony-forming units (CFUs)/mL. K562 rransduction. At 80% confluence, amphotropic vM5-MGMT producer cells were treated with 10 pg/mL mitomycin C for 2 hours, washed 4 times in serum-containing medium, trypsinized, and replated in complete medium. Twenty-four hours later, 2.5 X 105/mL K562 cells were added along with human interleukin-3 (IL-3) (100 U/mL, kindly provided by Genetics Institute, Cambridge, MA), GM-CSF (100 U/mL, kindly provided by Sandoz Research Institute, Nutley, NJ) and 6 pg/mL polybrene. Forty-eight hours later, the nonadherent K562 cells were procured and either analyzed for gene transfer or grown in medium containing 500 pg/mL G4 18. Selected cells were analyzed after 4 weeks.
Transduction of mouse BM cells. Murine BM was transduced as described by other^.^"^^ Briefly, 48 hours after treatment with 150 mg/kg 5-fluorouracil (5-FU) intraperitoneally, BM was procured from 8-to 10-week-old C3WHEN mice (Charles River, North Willmington, MA) and prestimulated at 1 X lo6 cells/mL in complete medium for 48 hours with murine stem cell factor (SCF) (kindly provided by Amgen [Thousand Oaks, CA]), murine IL-3 and murine IL-6 (both kindly provided by DNAX, Palo Alto, CA). These cells were then cocultured for 48 hours on mitomycin C-treated (see above) ecotropic vM5MGMT or vM5lac retroviral producer cells or blank plates (mock infected) in fresh cytokines and polybrene. The cells were then procured and analyzed for BCNU resistance or transplanted into lethally irradiated mice.
In vitro BCNU treatmenr. The 1.5 X lo6 vM5MGMT-infected or vM5lac-infected murine BM cells or 6 X 10' vM5MGMT-infected or uninfected K562 cells were resuspended in serum-free media. BCNU was dissolved in ethanol, diluted in serum free media, and added to the cell cultures within 10 minutes of reconstitution. The cells were incubated for 2 hours at 37°C. procured, and washed in serum-free media. Mouse BM cells (1 X 10') were mixed with methylcellulose, SCF (100 ng/mL), IL-3 (I 00 U/mL), and pokeweed For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 3344 ALLAY ET AL mitogen spleen cell-conditioned media (Terry Fox Laboratories, Stem Cell Technologies, Vancouver, BC, Canada) and plated in triplicate at 37°C in 5% COz. Five-hundred K562 cells were mixed with methylcellulose, hIL-3 (100 U/mL), and GM-CSF (100 UlmL) and plated in triplicate at 37°C in 5% COz. After 10 to 12 days, colonies greater than 50 cells were enumerated and large colonies were picked for PCR analysis of proviral integration. For murine BM cultures, 10 to 12 pooled colonies were assayed for MGMT expression by RNA-PCR. Differential survival between treatment groups was analyzed by paired t-test of the mean BCNU ICso and comparisons at each dose of BCNU.
EM rransplantation. Eight-to ten-week-old C3WHEN mice were lethally irradiated (1,050 rad, Cobalt source) and transplanted 4 hours later with 0.5 to 1.0 X IO' retrovirally or mock-transduced BM cells or BM cells procured from primary transplant recipients. All animals were housed in microisolator cages and given sterile rodent chow ad libitum with drinking water supplemented with 20 U/mL bacitracin and 4 mg/mL neomycin for one week before and three weeks after transplant. To enrich for transduced BM progenitor cells expressing MGMT in vivo, transplanted mice were treated with 5, 10, 15, or 25 mgkg BCNU intraperitoneally 2 to 10 weeks after transplantation. Because the aim of these experiments was to enhance transduction and expression, all mice received BCNU before analysis.
Spleen CFU (CFU-S)assay. Eight-to ten-week-old C3HfHEN mice were lethally irradiated (1,050 rad, Cobalt source) and transplanted with S X lo4 BM cells. After 12 days, the mice were killed and spleen colonies were enumerated under a dissecting microscope. The colonies were isolated for further analysis.
PCR provirus analysis. DNA was prepared from tissues using 1 mg/mL proteinase K in a buffer containing 50 mmol/L TRIS-HCI pH 8.0, 10 mmol/L EDTA, 100 mmol/L NaC1, and 1% Triton X-100. Samples were incubated 12 to 18 hours at 5 5 T , a 1:5 dilution in H20 was boiled and IO pL was used for PCR (E. McGuire, University of Pittsburgh, personal communication, December 1992). Blood cells were prepared by diluting 10 pL of blood in 400 pL of 10 mmol/L EDTA and 10 mmol/L NaCI, washing twice, resuspending in water, and boiling for 3 minutes. A 350-bp mouse P-globin fragment was amplified using the proximal primer 5' GAAGITGGGTGCTTGGAGAC 3', distal primer 5' GAGCATGC-TCCCTAGAATCG 3'. a 152-bp human MGMT fragment was amplified using the proximal primer S' C'ITCACCATCCCGT'XTTC-CAG 3', distal primer 5' CTTCTCATTGCTCCTCCCACT 3'. and/ or a 800-bp neo fragment was amplified using the proximal primer 5' CAAGATGGAGG'ITCTCCG 3' and distal primer 5' CCAGAG-TCCCGCTCAGAAGAACTCGTC 3'. The fragments were separated on a 2% agarose gel and detected by either ethidium bromide stain or Southern blot.
RNA-PCR. Purified total RNA or RNA prepared using the proteinase W r i t o n X-100 method (as above) was digested extensively (30 to 60 minutes) with DNase1 (amplification grade; BRL, Gaithersberg, MD) according to the manufacturer's instructions. Reverse transcription and PCR were performed using the Perkin-Elmer Cetus (Norwalk, CT) RNA-PCR kit following the manufacturer's instructions. Under these conditions, PCR without reverse transcriptase failed to amplify, indicating complete DNA digestion.
Alkyltransferase assay. Tissue alkyltransferase was measured as previously described." Briefly, enzyme activity was measured as t3H]-rnethyl groups removed from [3H]-06-MeG present in calf thymus DNA alkylated with [3H]-methylnitrosourea (specific activity of 0.047 fmol O6-MeG/1 pg DNA). The alkylated ['H]-06-MeG and N7-methylguanine bases were separated by high-performance liquid chromatography (HPLC) and quantified by liquid scintillation. N7methylguanine was used as the internal standard. Alkyltransferase activity was expressed as fmol O'-MeG removed/l pg DNA. All assays were repeated two to five times per sample.
Western blots. Tissues were lysed by sonication and boiling in a buffer containing 50 m m o w TRIS-HCI, pH 6.3,2% sodium dodecyl sulfate (SDS), 1 % P-mercaptoethanol, 0.1 m o m dithiothreitol (DTT), S% sucrose, and 300 pmol/L Na02 thovanadate. Total protein was quantitated by a modified Bradford assay (Bio-Rad Laboratories, Hercules, CA), and 30 to 50 pg of denatured protein was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted onto Immobilon PC (S&S, Keene, NH). Human alkyltransferase was detected using the monoclonal antibody (MoAb) MT3.1M (kindly provided by D. Bigner and T. Brent). Signal was detected using a goat-antimouse IgG conjugated to horseradish peroxidase and developed via chemiluminescence using the ECL kit from Amersham according to the manufacturer's instructions. Band intensity was quantified using a standard curve of cell extract from K562 cells infected with vM5MGMT that express high levels of MGMT, using a Bio-Rad densitometer.
RESULTS
Retroviral vector expression
in K562 cells. Ecotropic and amphotropic vM5MGMT producer cell lines derived from GP + E86 and GP + envAM12, respectively, were established by transfection of the pM5MGMT plasmid ( Fig  1) . Viral supernatant was collected daily for 6 days from producer cells that were initially 80% confluent. The viral titer increased over a 6-day period: fourfold in ecotropic producers (0.5 -+ 0.3 to 2.2 ? 0.1 X lo6 CFU/mL; n = 3), and 2.5-fold in amphotropic producers (0.5 2 0.6 to 1.2 2 0.5 X lo6 CFU/mL;n = 3). Supernatants collected on days 4 through 6 were used for the gene-transfer experiments. All assays for replication competent retrovirus, both in vitro and in vivo, were negative throughout this study.
To determine viral integration and expression in hematopoietic cells, vM5MGMT-transduced, G418-selected K562 cells were examined. Southern blots showed intact genomic provirus, and Northern blots showed intact full length and correctly spliced viral transcripts (data not shown).
vM5MGMT infection of K562 results in BCNU resistance. To determine whether alkyltransferase expression from vMSMGMT in K562 cells increased resistance to nitrosoureas, K562-and vM5MGMT-transduced K562 cells were exposed to increasing concentrations of BCNU and then plated in methylcellulose. Figure 2 shows that uninfected K562 cells had an ICso of 1.5 pmoVL BCNU, whereas vM5MGMT-infected, unselected K562 cells had an IC5o of 4.7 y m o E BCNU ( P .02), and infected cells selected for 4 weeks in G418 had an IC500f 32 ymoVL BCNU (P = .001). Similar results were obtained in cells evaluated for the neo gene G418 resistance (data not shown).
Infection and expression of vM5MGMT in primary murine hematopoietic progenitor cells.
Primary murine hematopoietic cells were infected as described in Materials and Methods. To detect provirus in colony-forming unit-cell 
In vivo persistence of vMSMGMT provirus in murine hematopoietic cells.
Lethally irradiated mice were transplanted with vM5MGMT-transduced BM. Because enrichment was noted after G418 selection of vM5MGMT-transduced K562 cells in vitro (Fig 2) all mice were treated with BCNU ip at 2, 4, and/or I O weeks after transplantation. Twenty-four transplant recipients were killed and analyzed between 7 and 54 weeks after transplantation for proviral integration and expression in hematopoietic tissues. Overall, Lethally irradiated mice were transplanted with BM transduced with vM5MGMT (weeks 7 through 54). Secondary BMT recipients (weeks 8 through 56) were transplanted with vM5MGMT-transduced BM from primary transplant recipients. All mice were killed at indicated times and BM, spleen, thymus, peripheral blood, and BM-derived progenitors (CFU-C, CFU-S12) were analyzed for vM5MGMT proviral presence by PCR. The proportion of samples with evidence of provirus by PCR are shown. Figure 5B shows a representative PCR of the presence of provirus in CFU-C.
BM was procured from one mouse per time point at 7, 16, and 32 weeks after transplantation to assay for the provirus in CFU-S,2 and to generate seven secondary transplant recipients. As indicated in Table 1 and representative data shown in Fig 6C, the majority of CFU& contained an integrated provirus detected by PCR. In addition, a large majority of BM, BM-derived progenitors, spleen, and thymus samples from these mice showed evidence of persistent proviral integration by PCR.
In vivo expression of the transduced human MGMT cDNA. The composite data for expression by RNA-PCR and Westem blot are shown in Table 2 was detected in the BM and thymus up to 23 weeks after transplantation in 11/14 mice, and in the spleens of 15/18 mice up to 37 weeks. Similarly, the majority of hematopoietic progenitors (CFU-C and CFU-S12) assayed showed MGMT expression (Fig 7) . Alkyltransferase activity was markedly increased in BM, spleen, and thymus as shown in Fig 6, reaching mean values of 839 fmol/yg protein in BM, 40-fold above endogenous levels (21 fmol/yg protein); 8 10 fmol/yg protein in spleen,lO-fold above endogenous levels (78 fmollyg protein); and 1 183 fmol/yg protein in thymus, 14-fold above endogenous levels (87 fmol/pg protein). Given the high rate of gene transduction and expression, no change in alkyltransferase was noted in mice exposed to high doses of BCNU.
. Expression from vM5MGMT
To assess whether BM progenitors from mice that were recipients of vMSMGMT-transduced BM were resistant to BCNU-induced cytotoxicity, we determined the BCNU survival of marrow-derived CFU-C. All animals with detectable vMSMGMT proviral integration and expression in the BM had increased survival after BCNU exposure relative to uninfected or vM5lac infected controls assayed concurrently. Figure 8 shows a representative experiment using BM from mice transplanted 18 weeks earlier with vM5MGMT-or vMSlac-transduced marrow. MGMT expressing mice had increased resistance to BCNU, with an increase in the BCNU ICso from 5 to 9 ymol/L. A small proportion of progenitors appeared particularly resistant with 3% and 1 o/o CFU-C survival at 40 and 50 ymol/L, respectively, in the vM5MGMT group compared with none in the vMSlac group. Overall, the mean BCNU ICso for the vM5MGMT-transduced BM was 13.2 pmol/L, whereas for mock or vM5lac-transduced BM, the mean BCNU ICso was 9.7 ymol/L (four independent, paired viral transductionhansplantation experiments, a total of six mice transplanted with vMSMGMT-transduced BM, and four mice transplanted with vMSlac, or mock transduced BM, P = .OOOS). At all concentrations of BCNU examined, the BM progenitors from mice transplanted with vM5MGMT-transduced BM had a significantly greater survival than the concurrent controls ( P < .01).
DISCUSSION
In these studies the MPSV-based retroviral vector, vMSMGMT, was used to increase alkyltransferase expression and reduce nitrosourea induced cytotoxicity in human and mouse hematopoietic cells. Amphotropic vM5MGMT transduced K562 cells showed significantly increased BCNU resistance immediately after transduction relative to untransduced K562 cells. After G418 selection, these cells had extremely high levels of alkyltransferase activity and the BCNU ICso was over 15-fold higher than in untransduced K562 cells. Primary murine BM cells transduced with ecotropic vM5MGMT express human alkyltransferase in vitro and in vivo at high levels for prolonged periods of time in multiple hematopoietic lineages after BM transplantation. vM5MGMT-transduced BM progenitor cells also had increased resistance to BCNU relative to mock and vM5lactransduced BM progenitors both in vitro and in vivo.
The MPSV LTR derived from pM5neo contains a point mutation in the enhancer region that creates an additional SPI binding This additional transcriptional enhancer binding site has been hypothesized to be responsible for the increase in its expression in many hematopoietic cell lines,"6 and in mouse BM and BM-derived progenitors J7 when compared with the MoMuLV LTR or other internal promoters. In addition, expression in embryonic carcinoma cells from pM5neo-derived vectors have been de~cribed?~ whereas many MoMuLV vectors are transcriptionally silent in these precursor These factors make MPSV vectors attractive for gene therapy where high expression of the transduced gene is required.
In our studies, the most striking result was that vM5MGMT transduction of hematopoietic progenitors resulted in a 10-to 40-fold increase over endogenous alkyltransferase levels in lymphoid and myeloid cells in vivo, representing a significant increase in the DNA repair capacity of 06-guanine adducts in these cells. In previous studies, transgenic mice and cell lines that overexpressed MGMT had increased repair of both 06mG adducts after methylating agent exposure and 06-chloroethyl precrosslink lesions after BCNU exposure.2s24 In hematopoietic progenitors, increased DNA repair capacity should increase drug resistance and protect cells from the mutagenic and carcinogenic effects of these adducts.
To enrich for high expressing cells, selection was applied to transduced K562 cells in vitro. vM5MGMT transduced, G41 8-selected K562 cells had very high alkyltransferase levels, reaching levels seen in MGMT transfected CH0 cellsz3 and the thymus of mice transgenic for the MGMT-CD2 gene.z4 These K562 cells also had high levels of expression of the neo gene from the MPSV LTR. Northern analysis showed approximately equal abundance of the full length and spliced proviral mRNA (J.A. Allay, S.L. Gerson, manuscript in preparation). Thus, with this vector, selection in G418 did not alter the production of full-length mRNA encoding MGMT from the provirus.
Based on these results, the mouse transplant studies were designed to select for cells expressing the MGMT transgene by treating the mice with BCNU after reconstitution. As noted above, mouse tissue expression of MGMT resulted in a marked increase in alkyltransferase activity over endogenous levels. Nonetheless, because there was no other selection, these hematopoietic tissues most likely contain cells with quite variable expression of the two transduced genes. This limits measurements of efficacy based on myelosuppression because many cells would not express levels of MGMT necessary for detectable drug resistance.
We were interested in the issue of in vivo selection of hematopoietic precursors expressing MGMT. However, only 3 of 24 mice transplanted with MGMT transduced cells did not receive BCNU. In general, we achieved a high level of gene transfer and high mean levels of alkyltransferase expression in MGMT transplanted mice after BCNU treatment. We were unable to detect a difference in mice left untreated compared with mice treated with BCNU in BM cellularity or in the proportion of CFU-C that was either proviral positive or more resistant to BCNU in vitro. However, of note, four mice (1/3 untreated and 3/21 exposed to BCNU) had evidence of poor gene transfer efficiency, ie, BM CFU-C had low or no vMSMGMT transduction and showed no expression of human alkyltransferase, and there was no evidence of proviral presence and low or no human alkyltransferase expression in hematopoietic tissues. These mice had no evidence of increased CFU-C resistance to BCNU in vitro over that observed in control mice. In contrast, when provirus was detected, CFU-C expressed MGMT and had increased BCNU resistance.
While this suggests that MGMT gene transduction was associated with BCNU resistance, a direct comparison of vM5MGMT transduced progenitors between transplanted mice with or without BCNU administration was not per- formed. In vivo selection of genetically transduced cells expressing MGMT would require a large cohort of transplanted mice, half of which would receive repeated doses of BCNU, using endpoints of white blood cells, marrow cellularity and in vitro BCNU resistance of CFU-C. Animals receiving repeated doses of BCNU would be expected to more uniformly express alkyltransferase. An alternative strategy would be to use an alkyltransferase molecule that is resistant to the inhibitor O%enzylguanine," such as the bacterial:' mouse:' or mutant forms of the human alkyltransferase?* These recently described mutants should enhance the survival advantage of transduced cells after treatment with the combination of 06-benzylguanine and BCNU compared with that seen with BCNU alone.
Our data indicate a modest but significant increase in BCNU resistance in BM progenitors from vMSMGMT transplanted mice relative to vM5lac or mock-transplanted mice.The degree of protection is somewhat less than might have been predicted by the increase in repair capacity, and could be the result of several parameters involving alkylation of DNA by BCNU and its repair. First, the major cytotoxic lesion induced by BCNU is the interstrand DNA cross-link.'* Because the preferred substrate of the alkyltransferase is the 06-methylguanine repair of the precross-link adduct may occur at a slower rate allowing some cross-links to form even in the presence of the active enzyme. Second, because 06-chloroethylguanine is a minor alkylation product of chloroethylnitroso~reas~~ there may be additional BCNUinduced cytotoxic lesions not repairable by MGMT.
The relative increase in BCNU resistance was greater in K562 cells than murine BM after vM5MGMT transduction. This can be attributed to the fact that murine BM cells have low but detectable endogenous alkyltransferase levels, io io 30 40 50 BCNU pM D whereas K562 cells lack activity completely, and also that other potential resistance mechanisms to BCNU cytotoxicity may not be present in K562 cells, whereas they may be operative in normal hematopoietic precursors. For instance, we previously reported that treatment of K562 cells with an alkyltransferase inhibito8' did not sensitize these cells to BCNU, whereas inhibiting alkyltransferase in BM progenitors resulted in a 2to 3-fold reduction in their BCNU LDso. Even after alkyltransferase depletion, BM progenitors remained more resistant to BCNU than K562 cells.M This indicates that other repair mechanisms such as nucleotide excision repair?' g1utathione?' glutathione-S-transfera~e~~ and pol yami nes, @' which have been shown to play a role in chloroethylnitrosourea resistance in some tumors, may play a role in BCNU resistance in BM progenitors.
The observation that vMSMGMT transduction increases alkyltransferase levels and BCNU resistance in murine and human hematopoietic cells has led us to evaluate transduction of human CD34' hematopoietic precursors with the anticipation that similar protection from BCNU-induced cytotoxicity will occur.
